Michael Gottschalk
Pediatric Endocrinology · San Diego, CANPI 1033280888
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (39.1%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Daiichi Sankyo Inc. at 40.9% of the total. Reporting peaked in 2020 at $5,616 and has fallen 95.6% since, to $245 in 2025.
Across 133 payments — averaging $125.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$7K
- Rhythm Pharmaceuticals, Inc.$2K
- Ipsen Biopharmaceuticals, Inc$2K
- Eli Lilly$1K
- Sanofi-aventis U.S. LLC$742
- Mannkind Corporation$728
- plus $2K from 16 others
Across 343 payments — averaging $6860.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Rhythm Pharmaceuticals, Inc.$865K
- Eli Lilly$582K
- Sanofi US Services Inc.$435K
- Mannkind Corporation$153K
- Ultragenyx Pharmaceutical Inc.$126K
- Boehringer Ingelheim$82K
- plus $110K from 5 others
What the payments were for
- Consulting fees$6,52039%
- Speaking & faculty fees$2,02012%
- Travel & lodging$2,75117%
- Food & beverage$3,07118%
- Education$2,18013%
- Gifts$1191%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 10 | $6,822 |
| Rhythm Pharmaceuticals, Inc. | 3 | $2,445 |
| Ipsen Biopharmaceuticals, Inc | 10 | $2,257 |
| Eli Lilly | 6 | $1,385 |
| Sanofi-aventis U.S. LLC | 4 | $742 |
| Mannkind Corporation | 4 | $728 |
| Novo Nordisk | 26 | $571 |
| Dexcom, Inc. | 13 | $283 |
| Ferring Pharmaceuticals Inc. | 10 | $260 |
| AbbVie | 10 | $222 |
| Insulet Corporation | 9 | $161 |
| Abbott | 1 | $150 |
| Azurity Pharmaceuticals, Inc. | 8 | $144 |
| Eton Pharmaceuticals, Inc. | 2 | $123 |
| Medtronic(2 entities) | 5 | $101 |
| BETA Bionics, Inc. | 3 | $84 |
| Sandoz | 2 | $45 |
| Tandem Diabetes Care, Inc. | 2 | $38 |
| Biomarin Pharmaceutical Inc. | 1 | $30 |
| Pfizer | 2 | $28 |
| Neurocrine Biosciences, Inc. | 1 | $26 |
| Soleno Therapeutics, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,661 in reported general payments places this provider in the 85th percentile of 168 pediatric endocrinology providers in California.
Other pediatric endocrinology in San Diego
- Karen KleinSan Diego$195K
- Marcela Vargas TrujilloSan Diego$57K
- Ron NewfieldSan Diego$27K
- Susan PhillipsSan Diego$12K
- Maja MarinkovicSan Diego$5K
- Mary PattersonSan Diego$4K
- Jane KimSan Diego$3K
- Gnanagurdasan PrakasamSacramento$805K
- Swati ElchuriVentura$210K
- Francine KaufmanLos Angeles$184K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.